NO311285B1 - Anvendelse av trippelterapiregime bestående av spiramycin, metronidazol og et antiulcermiddel - Google Patents
Anvendelse av trippelterapiregime bestående av spiramycin, metronidazol og et antiulcermiddel Download PDFInfo
- Publication number
- NO311285B1 NO311285B1 NO19964252A NO964252A NO311285B1 NO 311285 B1 NO311285 B1 NO 311285B1 NO 19964252 A NO19964252 A NO 19964252A NO 964252 A NO964252 A NO 964252A NO 311285 B1 NO311285 B1 NO 311285B1
- Authority
- NO
- Norway
- Prior art keywords
- spiramycin
- metronidazole
- patients
- treatment
- helicobacter pylori
- Prior art date
Links
- 239000004187 Spiramycin Substances 0.000 title claims abstract description 21
- 229960001294 spiramycin Drugs 0.000 title claims abstract description 21
- 229930191512 spiramycin Natural products 0.000 title claims abstract description 20
- 235000019372 spiramycin Nutrition 0.000 title claims abstract description 20
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229960000282 metronidazole Drugs 0.000 title claims abstract description 17
- 239000003699 antiulcer agent Substances 0.000 title claims abstract description 12
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 title claims abstract 6
- 238000002560 therapeutic procedure Methods 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 claims description 24
- 241000590002 Helicobacter pylori Species 0.000 claims description 16
- 229940037467 helicobacter pylori Drugs 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 7
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 229940069428 antacid Drugs 0.000 claims description 4
- 239000003159 antacid agent Substances 0.000 claims description 4
- 229960001482 bismuth subnitrate Drugs 0.000 claims description 4
- 230000001458 anti-acid effect Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 241000589989 Helicobacter Species 0.000 abstract 1
- XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- ACTOXUHEUCPTEW-CEUOBAOPSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-CEUOBAOPSA-N 0.000 description 15
- 208000025865 Ulcer Diseases 0.000 description 10
- 230000008029 eradication Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- 208000008469 Peptic Ulcer Diseases 0.000 description 6
- 108010046334 Urease Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 208000011906 peptic ulcer disease Diseases 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 150000001621 bismuth Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187758 Streptomyces ambofaciens Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229940063190 flagyl Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940087275 spiramycin and metronidazole Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9404952A FR2718965B1 (fr) | 1994-04-25 | 1994-04-25 | Nouvelle application thérapeutique de la spiramycine. |
| PCT/FR1995/000533 WO1995028943A1 (fr) | 1994-04-25 | 1995-04-24 | UTILISATION DE LA SPIRAMYCINE DANS DES DESORDRES GASTROINTESTINAUX DUS A $i(H. PYROLI) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964252L NO964252L (no) | 1996-10-07 |
| NO964252D0 NO964252D0 (no) | 1996-10-07 |
| NO311285B1 true NO311285B1 (no) | 2001-11-12 |
Family
ID=9462476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964252A NO311285B1 (no) | 1994-04-25 | 1996-10-07 | Anvendelse av trippelterapiregime bestående av spiramycin, metronidazol og et antiulcermiddel |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6162792A (ja) |
| EP (1) | EP0758245B1 (ja) |
| JP (2) | JP3937448B2 (ja) |
| KR (1) | KR970702054A (ja) |
| CN (1) | CN1147204A (ja) |
| AT (1) | ATE234619T1 (ja) |
| AU (1) | AU2412795A (ja) |
| BR (1) | BR9507848A (ja) |
| CA (1) | CA2188697A1 (ja) |
| DE (1) | DE69529981T2 (ja) |
| DK (1) | DK0758245T3 (ja) |
| ES (1) | ES2194907T3 (ja) |
| FR (1) | FR2718965B1 (ja) |
| NO (1) | NO311285B1 (ja) |
| PT (1) | PT758245E (ja) |
| WO (1) | WO1995028943A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN190017B (ja) | 1999-01-25 | 2003-05-31 | Panacea Biotech Ltd | |
| US6576625B2 (en) | 2001-03-16 | 2003-06-10 | Panacea Biotic Limited | Targeted vesicular constructs for cytoprotection and treatment of H. pylori infections |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0375068A1 (en) * | 1988-12-23 | 1990-06-27 | Gist-Brocades N.V. | Combining bismuth compounds and tetracyclines |
-
1994
- 1994-04-25 FR FR9404952A patent/FR2718965B1/fr not_active Expired - Lifetime
-
1995
- 1995-04-24 AU AU24127/95A patent/AU2412795A/en not_active Abandoned
- 1995-04-24 PT PT95918047T patent/PT758245E/pt unknown
- 1995-04-24 KR KR1019960705982A patent/KR970702054A/ko not_active Application Discontinuation
- 1995-04-24 EP EP95918047A patent/EP0758245B1/fr not_active Expired - Lifetime
- 1995-04-24 US US08/727,466 patent/US6162792A/en not_active Expired - Lifetime
- 1995-04-24 CN CN95192781A patent/CN1147204A/zh active Pending
- 1995-04-24 CA CA002188697A patent/CA2188697A1/fr not_active Abandoned
- 1995-04-24 WO PCT/FR1995/000533 patent/WO1995028943A1/fr active IP Right Grant
- 1995-04-24 ES ES95918047T patent/ES2194907T3/es not_active Expired - Lifetime
- 1995-04-24 DK DK95918047T patent/DK0758245T3/da active
- 1995-04-24 BR BR9507848A patent/BR9507848A/pt not_active Application Discontinuation
- 1995-04-24 DE DE69529981T patent/DE69529981T2/de not_active Expired - Lifetime
- 1995-04-24 JP JP52740895A patent/JP3937448B2/ja not_active Expired - Lifetime
- 1995-04-24 AT AT95918047T patent/ATE234619T1/de active
-
1996
- 1996-10-07 NO NO19964252A patent/NO311285B1/no not_active IP Right Cessation
-
2007
- 2007-01-12 JP JP2007004854A patent/JP2007091761A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2194907T3 (es) | 2003-12-01 |
| FR2718965A1 (fr) | 1995-10-27 |
| DE69529981T2 (de) | 2003-12-04 |
| EP0758245B1 (fr) | 2003-03-19 |
| WO1995028943A1 (fr) | 1995-11-02 |
| ATE234619T1 (de) | 2003-04-15 |
| AU2412795A (en) | 1995-11-16 |
| DK0758245T3 (da) | 2003-07-07 |
| EP0758245A1 (fr) | 1997-02-19 |
| US6162792A (en) | 2000-12-19 |
| PT758245E (pt) | 2003-08-29 |
| JP2007091761A (ja) | 2007-04-12 |
| CA2188697A1 (fr) | 1995-11-02 |
| NO964252L (no) | 1996-10-07 |
| FR2718965B1 (fr) | 1996-05-24 |
| JPH09512262A (ja) | 1997-12-09 |
| BR9507848A (pt) | 1997-09-16 |
| DE69529981D1 (de) | 2003-04-24 |
| JP3937448B2 (ja) | 2007-06-27 |
| CN1147204A (zh) | 1997-04-09 |
| KR970702054A (ko) | 1997-05-13 |
| NO964252D0 (no) | 1996-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hosking et al. | Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial | |
| De Boer et al. | Only four days of quadruple therapy can effectively cure Helicobacter pylori infection | |
| Sung et al. | One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding | |
| Zimmon et al. | Specific inhibition of gastric pepsin in the treatment of gastric ulcer | |
| Xia et al. | Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer | |
| CA2344308C (en) | Taurolidine and/or taurultam against infectious ulcer or gastritis | |
| Castro-Fernández et al. | Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori | |
| Atherton et al. | Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals | |
| JP7189327B2 (ja) | ヘリコバクターピロリ菌を除菌するための組成物 | |
| Gupta et al. | Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. | |
| NO311285B1 (no) | Anvendelse av trippelterapiregime bestående av spiramycin, metronidazol og et antiulcermiddel | |
| Tomita et al. | Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease | |
| Boer et al. | Four‐day quadruple therapy as a routine treatment for Helicobacter pylori infection | |
| Garcia et al. | Limited usefulness of a seven-day twice-a-day quadruple therapy | |
| Lam et al. | Sucralfate compared with ranitidine in the short-term healing of duodenal ulcers | |
| MXPA96004986A (es) | Utilizacion de espiramicina en transtornos gastrointestinales causados por h. pylori | |
| Kolkman et al. | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection | |
| Parente et al. | Colloidal Bismuth Subcitrate and Ranitidne in the Short-Term Treatment of Benign Gastric Ulcer an Endoscopically Controlled Trial | |
| Akcan et al. | The Transmission ofHelicobacter PyloriVia Exposure To Common Sources Outweighs The Person-To-Person Contact Among Spouses in Developing Countries | |
| RU2315596C1 (ru) | Фармацевтическая композиция, обладающая антацидным и репаративным действием, получение и применение | |
| WO1998023272A1 (en) | Compositions and methods for the treatment of gastrointestinal disorders | |
| Casey | Gastritis and proton pump inhibitors | |
| Quinton et al. | Treatment of benign gastric ulcer: a comparative clinical trial of rioprostil and ranitidine | |
| Smoot et al. | Effectiveness of Ranitidine Bismuth Citrate, Clarithromycin, and Metronidazole Therapy for TreatingHelicobacter pylori | |
| RU2278682C2 (ru) | Способ лечения воспалительных заболеваний желудочно-кишечного тракта, ассоциированных с helicobacter pylori |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |